1-(1-Azidocyclohexyl)adamantane | 1621387-65-2

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 1-(1-Azidocyclohexyl)adamantane
• 英文别名: 1-(1-azidocyclohexyl)adamantane
• CAS: 1621387-65-2
• 化学式: C₁₆H₂₅N₃
• 分子量: 259.395
• InChiKey: GKTXIEAMKIYRDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  14.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-Azidocyclohexyl)adamantane 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 5.0h， 以30%的产率得到1-(1-adamantyl)cyclohexanamine
  参考文献：
  名称：

  以伯叔烷基胺为基石的方法

  摘要：

  初级叔烷基胺包括金刚烷胺的类似物，通常连接到药效基团的片段，以提高生物活性。伯叔烷基胺的制备被认为是一个难题。四个合成步骤，其中一些已经用于与胺的合成已有报道初级（RCH 2 NH 2）或仲（RR'CHNH 2）烷基和/或芳基，伯合成进行了测试叔烷基胺（RR'R''CNH 2）包括金刚烷加合物在内的脂族系列。这些程序包括在形成和还原的叔烷基叠氮化物，在标准和改良条件Ritter反应，在加入有机金属试剂以ñ -叔丁基亚磺酰基酮亚胺和一锅在路易斯酸的存在下，Τi（IPRO）腈和有机金属试剂之间的反应4或CeCl 3.对于伯叔烷基胺，尚未开发这些合成途径。当前缺乏对伯叔烷基胺的合成路线的研究。研究了每种方法的反应条件和底物限制，第一种方法是最通用的方法，也适用于带有大分子加合物的化合物。

  DOI：

  10.1016/j.tet.2019.06.016
• 作为产物：
  描述：

  1-溴金刚烷 在 sodium azide 、 lithium 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 28.0h， 生成 1-(1-Azidocyclohexyl)adamantane
  参考文献：
  名称：

  Binding and Proton Blockage by Amantadine Variants of the Influenza M2_WT and M2_S31N Explained

  摘要：

  While aminoadamantanes are well-established inhibitors of the influenza A M2 proton channel, the mechanisms by which they are rendered ineffective against M2(s31N) are unclear. Solid state NMR, isothermal titration calorimetry, electrophysiology, antiviral assays, and molecular dynamics simulations suggest stronger binding interactions for aminoadamantanes to M2(WT). compared to negligible or weak binding to M2s31N. This is due to reshaping of the M2 pore when N31 is present, which, in contrast to wild-type (WT), leads (A) to the loss of the V27 pocket for the adamantyl cage and to a predominant orientation of the ligand's ammonium group toward the N-terminus and (B) to the lack of a helical kink upon ligand binding. The kink, which reduces the tilt of the C-terminal helical domain relative to the bilayer normal, includes the W41 primary gate for proton conductance and may prevent the gate from opening, representing an alternative view for how these drugs prevent proton conductance.

  DOI：

  10.1021/acs.jmedchem.6b01115

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：BRIGHAM YOUNG UNIVERSITY

  公开号：US20150368196A1

  公开（公告）日：2015-12-24

  Compounds useful for treating and preventing viral infections including influenza are disclosed. Methods of treating or preventing viral infections, including influenza A infections are disclosed. Specifically, aminoadamantane derivatives that are structurally analogous to amantadine, including spirocyclic compounds, are provided for the treatment of amantadine-insensitive influenza infection in a subject.

  本文披露了用于治疗和预防包括流感在内的病毒感染的化合物。本文还披露了治疗或预防病毒感染，包括甲型流感感染的方法。具体而言，提供了与金刚烷胺结构类似的氨基金刚烷衍生物，包括螺环化合物，用于治疗对金刚烷胺不敏感的流感感染。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：UNIV BRIGHAM YOUNG

  公开号：WO2014121170A3

  公开（公告）日：2014-11-20
• US9840465B2
  申请人：——

  公开号：US9840465B2

  公开（公告）日：2017-12-12
• Approaches to primary tert-alkyl amines as building blocks
  作者：Christina Tzitzoglaki、Antonios Drakopoulos、Athina Konstantinidi、Ioannis Stylianakis、Marianna Stampolaki、Antonios Kolocouris

  DOI：10.1016/j.tet.2019.06.016

  日期：2019.8

  Primary tert-alkyl amines include analogues of amantadine, a fragment commonly linked to pharmacophoric groups to enhance biological activity. The preparation of primary tert-alkyl amines is considered to be a difficult problem. Four synthetic procedures, some of which have been previously reported for the synthesis of amines with primary (RCH2NH2) or secondary (RR'CHNH2) alkyl and/or aryl groups,

  初级叔烷基胺包括金刚烷胺的类似物，通常连接到药效基团的片段，以提高生物活性。伯叔烷基胺的制备被认为是一个难题。四个合成步骤，其中一些已经用于与胺的合成已有报道初级（RCH 2 NH 2）或仲（RR'CHNH 2）烷基和/或芳基，伯合成进行了测试叔烷基胺（RR'R''CNH 2）包括金刚烷加合物在内的脂族系列。这些程序包括在形成和还原的叔烷基叠氮化物，在标准和改良条件Ritter反应，在加入有机金属试剂以ñ -叔丁基亚磺酰基酮亚胺和一锅在路易斯酸的存在下，Τi（IPRO）腈和有机金属试剂之间的反应4或CeCl 3.对于伯叔烷基胺，尚未开发这些合成途径。当前缺乏对伯叔烷基胺的合成路线的研究。研究了每种方法的反应条件和底物限制，第一种方法是最通用的方法，也适用于带有大分子加合物的化合物。
• Binding and Proton Blockage by Amantadine Variants of the Influenza M2_WT and M2_S31N Explained
  作者：Christina Tzitzoglaki、Anna Wright、Kathrin Freudenberger、Anja Hoffmann、Ian Tietjen、Ioannis Stylianakis、Felix Kolarov、David Fedida、Michaela Schmidtke、Günter Gauglitz、Timothy A. Cross、Antonios Kolocouris

  DOI：10.1021/acs.jmedchem.6b01115

  日期：2017.3.9

  While aminoadamantanes are well-established inhibitors of the influenza A M2 proton channel, the mechanisms by which they are rendered ineffective against M2(s31N) are unclear. Solid state NMR, isothermal titration calorimetry, electrophysiology, antiviral assays, and molecular dynamics simulations suggest stronger binding interactions for aminoadamantanes to M2(WT). compared to negligible or weak binding to M2s31N. This is due to reshaping of the M2 pore when N31 is present, which, in contrast to wild-type (WT), leads (A) to the loss of the V27 pocket for the adamantyl cage and to a predominant orientation of the ligand's ammonium group toward the N-terminus and (B) to the lack of a helical kink upon ligand binding. The kink, which reduces the tilt of the C-terminal helical domain relative to the bilayer normal, includes the W41 primary gate for proton conductance and may prevent the gate from opening, representing an alternative view for how these drugs prevent proton conductance.